The acquisition adds scale and diversification to create a stronger global diagnostics business, with a complementary suite of genomic technologies and services
Yourgene Health PLC (AIM:YGEN) Rule 2.7 Announcement
RECOMMENDED CASH OFFER by Novacyt UK Holdings Limited (a wholly-owned subsidiary of Novacyt S.A.) for Yourgene Health plc to be effected by means of a Scheme of Arrangement under Part
Mirada PLC – Proposed AIM cancellation & notice of GM
Proposed cancellation of admission to trading on AIM of ordinary shares, re-registration as a private limited company and adoption of new Articles of Association and
Novacyt S.A. Final Results, Full year revenue and EBITDA
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Novacyt S.A. (AIM:NCYT) DHSC Claim update – Trial date listed
Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt
Novacyt S.A. (AIM:NCYT) Approval of genesig COVID-19 3G PCR test in UK
Approval of genesig® COVID-19 3G PCR test in the UK under CTDA legislation
What Are the Best VDRs in the Market Today?
Automated data retrieval is a method of processing and storing primary documents. Data no longer needs to be stored as a traditional paper archive. Learn more about the best VDRs.
Novacyt S.A. (AIM:NCYT) UK Approval of genesig® SARS-CoV-2 Winterplex® 3G
A multiplex PCR test for the detection of winter viruses including SARS-CoV-2, influenza A and B, and RSV
Novacyt S.A. (AIM:NCYT) Launch of research-use-only adenovirus F41 assay
The assay has been developed by Novacyt to support research efforts following a recent increase in cases of acute hepatitis in children
Novacyt S.A. (AIM:NCYT) Approval of exsigT COVID-19 Direct test in the UK
Approval of exsig™ COVID-19 Direct test in the UK under CTDA legislation
Novacyt S.A. (AIM:NCYT) Trading update and progress against strategy
Trading update and progress against strategy for H1 2022